Fundz

AEON Biopharma Appoints Rob Bancroft as Chief Executive Officer

PRIVATEApr 22, 2025

Position

President

Company

AEON Biopharma

Rob Bancroft
IrvineBiotechnologyHealthcareHealth CareTherapeuticsBiopharma

Description

AEON Biopharma has announced the appointment of Rob Bancroft as President and Chief Executive Officer, effective April 29, 2025. Bancroft, an industry veteran with over 25 years of experience, will also join AEON's Board of Directors.

Quick answer

AEON Biopharma Appoints Rob Bancroft as Chief Executive Officer (April 22, 2025). AEON Biopharma is based in Irvine, California, United States.

Who is the new President at AEON Biopharma?
AEON Biopharma named Rob Bancroft President, announced April 22, 2025.
What did AEON Biopharma announce on April 22, 2025?
AEON Biopharma has announced the appointment of Rob Bancroft as President and Chief Executive Officer, effective April 29, 2025. Bancroft, an industry veteran with over 25 years of experience, will also join AEON's Board of Directors.
What does AEON Biopharma do?
AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial...
Where is AEON Biopharma based?
AEON Biopharma is based in Irvine, California, United States.
Which similar companies made leadership changes around the same time?
Madrigal Pharmaceuticals (April 16, 2025), Hansa Biopharma (April 24, 2025), Werewolf Therapeutics (April 17, 2025) and Inhibikase Therapeutics (April 14, 2025) also announced leadership changes within 45 days of AEON Biopharma.

Source: Fundz verified event record.

Other recent leadership changes in Healthcare and Therapeutics

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at AEON Biopharma, and when

A new leader at AEON Biopharma brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day AEON Biopharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at AEON Biopharma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at AEON Biopharma. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

AEON Biopharma

Location

5 PARK PLAZA

Irvine, California, United States

About

AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment AEON Biopharma changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Alex
Likely contact at this company
••••••••@••••••••

See Alex's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for AEON Biopharma's next move

Learn about Strategic plan

AEON Biopharma changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.